Navigation Links
Cedars-Sinai clinical trial studies vaccine targeting cancer stem cells in brain cancers

LOS ANGELES (Jan. 24, 2014) An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology.

Like normal stem cells, cancer stem cells have the ability to self-renew and generate new cells, but instead of producing healthy cells, they create cancer cells. In theory, if the cancer stem cells can be destroyed, a tumor may not be able to sustain itself, but if the cancer originators are not removed or destroyed, a tumor will continue to return despite the use of existing cancer-killing therapies.

The Phase I study, which will enroll about 45 patients and last two years, evaluates safety and dosing of a vaccine created individually for each participant and designed to boost the immune system's natural ability to protect the body against foreign invaders called antigens. The drug targets a protein, CD133, found on cancer stem cells of some brain tumors and other cancers.

Immune system cells called dendritic cells will be derived from each patient's blood, combined with commercially prepared glioblastoma proteins and grown in the laboratory before being injected under the skin as a vaccine weekly for four weeks and then once every two months, according to Jeremy Rudnick, MD, neuro-oncologist in the Cedars-Sinai Department of Neurosurgery and Department of Neurology, the study's principal investigator.

Dendritic cells are the immune system's most powerful antigen-presenting cells those responsible for helping the immune system recognize invaders. By being loaded with specific protein fragments of CD133, the dendritic cells become "trained" to recognize the antigen as a target and stimulate an immune response when they come in contact.

The cancer stem cell study is the latest evolution in Cedars-Sinai's history of dendritic cell vaccine research, which was introduced experimentally in patient trials in 1998.

Cedars-Sinai's brain cancer stem cell study is open to patients whose glioblastoma multiforme has returned following surgical removal. Potential participants will be screened for eligibility requirements and undergo evaluations and medical tests at regular intervals. The vaccine and study-related tests and follow-up care will be provided at no cost to patients. For more information, call 1-800-CEDARS-1 or contact Cherry Sanchez by phone at 310-423-8100 or email

The dendritic cell vaccine is produced by and the study is funded by ImmunoCellular Therapeutics, Ltd. Cedars-Sinai owns equity in the company, and certain rights in the dendritic cell vaccine technology and corresponding intellectual property have been exclusively licensed by Cedars-Sinai to ImmunoCellular Therapeutics, including subsequently developed versions of the vaccine investigated in this clinical study. None of the investigators in this trial (Jeremy Rudnick, MD; Jethro Hu, MD; Surasak Phuphanich, MD; and Ray Chu, MD) receives any funding from nor has any other financial interest in ImmunoCellular Therapeutics. Two Cedars-Sinai physicians, Keith Black, MD, and John Yu, MD, own stock in Immunocellular Therapeutics, but neither is an investigator on this trial. Yu is founder, chief scientific officer and chair of the board of directors of Immunocellular Therapeutics.


Contact: Sandy Van
Cedars-Sinai Medical Center

Related medicine news :

1. Update: 50 percent of patients in Cedars-Sinai brain cancer study alive after 5 years
2. Prominent Cedars-Sinai medical physicist receives highest honor from distinguished association
3. Cedars-Sinai opens first-of-its-kind trial in western US for metastatic carcinoid cancer patients
4. Heart valve repair innovator receives Cedars-Sinai Heart Institutes Corday Prize in Heart Research
5. Cedars-Sinai study: Obesity may be linked to microorganisms living in the gut
6. Nobel laureate Roger Tsien, Ph.D., keynotes Cedars-Sinai nanomedicine conference March 15, 16
7. Cedars-Sinai Heart Institute Physician Asher Kimchi, M.D., Insurance Entrepreneur Dianne Brinson to be Honored at HeartView Global Foundation’s Second Annual Gala
8. Cedars-Sinai physician-scientist awarded $3M to study most common inherited neurological disorder
9. Leading stem cell scientists to focus on diabetes, eye diseases at Cedars-Sinai symposium
10. Cedars-Sinai Heart Institute awarded $1.3 million to study cardiac stem cells
11. In war with superbugs, Cedars-Sinai researchers see new weapon: Immune-boosting vitamin
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: